AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AgomAb Therapeutics NV

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026

$8.23−0.05 (-0.60%)

Close on Oct 19, 2026

AgomAb Therapeutics NV revenue by segment

AgomAb Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.